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Background: Chronic obstructive pulmonary disease (COPD) is characterized by marked pheno-
typic heterogeneity. Most previous studies have focused on COPD subjects with FEV1 < 80% pre-
dicted. We investigated the clinical and genetic heterogeneity in subjects with mild airflow
limitation in spirometry grade 1 defined by the Global Initiative for chronic Obstructive Lung
Disease (GOLD 1).
Methods: Data from current and former smokers participating in the COPDGene Study
(NCT00608764) were analyzed. K-means clustering was performed to explore subtypes within
794 GOLD 1 subjects. For all subjects with GOLD 1 and with each cluster, a genome-wide as-
sociation study and candidate gene testing were performed using smokers with normal lung
function as a control group. Combinations of COPD genome-wide significant single nucleotide
polymorphisms (SNPs) were tested for association with FEV1 (% predicted) in GOLD 1 and in a
combined group of GOLD 1 and smoking control subjects.Pulmonary and Critical Care Medicine, School of Medicine, Ewha Womans University, 1071 Any-
8-710, Republic of Korea. Tel.: þ82 2 2650 6007; fax: þ82 2 2655 2076.
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x: þ1 617 525 0958.
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1470 J.H. Lee et al.Results: K-means clustering of GOLD 1 subjects identified putative “near-normal”, “airway-
predominant”, “emphysema-predominant” and “lowest FEV1% predicted” subtypes. In non-
Hispanic whites, the only SNP nominally associated with GOLD 1 status relative to smoking con-
trols was rs7671167 (FAM13A) in logistic regression models with adjustment for age, sex, pack-
years of smoking, and genetic ancestry. The emphysema-predominant GOLD 1 cluster was
nominally associated with rs7671167 (FAM13A) and rs161976 (BICD1). The lowest FEV1% pre-
dicted cluster was nominally associated with rs1980057 (HHIP) and rs1051730 (CHRNA3). Com-
binations of COPD genome-wide significant SNPs were associated with FEV1 (% predicted) in a
combined group of GOLD 1 and smoking control subjects.
Conclusions: Our results indicate that GOLD 1 subjects show substantial clinical heterogeneity,
which is at least partially related to genetic heterogeneity.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality worldwide,
which is characterized by persistent and usually progres-
sive airflow limitation. While cigarette smoking is a well-
known risk factor, large variability in the response to
cigarette smoke exists among individuals [1]. Although
chronic bronchitis and emphysema are two classic disease-
related characteristics of COPD [2], many different COPD-
related phenotypes have been suggested [3e9]. COPD
subjects with the same age, body mass index (BMI), and
lung function exhibit different levels of dyspnea, exacer-
bation frequency, exercise capacity, severity of emphy-
sema, and quality of life [10,11]. There have been many
reports investigating heterogeneity of COPD patients
[3e11]. However, most of them have focused on subjects
with an FEV1 < 80% predicted [6,7,10e14]. Studies of
COPD patients with relatively preserved FEV1 are rare
[15,16], yet these subjects make up a large proportion of
subjects with COPD as defined by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) [17,18]. The
FEV1/FVC ratio normally falls with increasing age [19], so
some fraction of individuals with reduced FEV1/FVC but
normal FEV1 are likely healthy [20,21]. However, some
GOLD 1 subjects will likely progress to moderate and even
severe COPD. Identification of the clinical, imaging, and
genetic characteristics of GOLD 1 subjects with progres-
sive disease could provide opportunities for early treat-
ment interventions.
To begin to understand the epidemiology and genetics
of COPD heterogeneity among individuals with mild
airflow limitation, we investigated subjects with
spirometry grade 1 defined by GOLD [17] in the COPDG-
ene Study. Our hypothesis was that there is identifiable
heterogeneity within GOLD 1 subjects, with some in-
dividuals having significant COPD and others being
healthy. We also hypothesized that there will be an as-
sociation of previously described single nucleotide poly-
morphisms (SNPs) [22e26] with COPD-related phenotypes
in GOLD 1 subjects.Methods
Study population
COPDGene (clinicaltrials.gov Identifier NCT00608764) is a
multicenter study designed to investigate the underlying
genetic determinants of COPD. Study details have been
described [27] and all protocols and questionnaires are
available at http://www.copdgene.org. All subjects were
self-identified non-Hispanic white (NHW) or African Amer-
ican (AA) between 45 and 80 years old and had at least 10
pack-years of cigarette smoking. Institutional review board
approval was obtained at each of the 21 participating
clinical centers; all subjects provided written informed
consent. Subjects completed questionnaires, pre- and post-
bronchodilator spirometry with quality control review, 6-
min walk test, and volumetric computed tomography (CT)
of the chest at both inspiration and expiration.
Variable definitions
Percent predicted values and lower limits of normal (LLN)
were calculated using post-bronchodilator spirometric values
[19]. Subjects with GOLD spirometry grade 1 were defined as
having post-bronchodilator FEV1  80% predicted with FEV1/
FVC< 0.7, and smoking controlsweredefinedas smokerswith
normal lung function (post-bronchodilator FEV1  80% with
FEV1/FVC  0.7). Among GOLD 1 subjects, LLN-defined sub-
groupswere defined as follows: LLN-COPD subjects had FEV1/
FVC < LLN and LLN-normal subjects had FEV1/FVC  LLN
based on Hankinson prediction equations [19].
Quantitative CT lung density measurements were per-
formed using Slicer (Version 2, www.slicer.org). Percent
emphysemawas calculatedas the percentage of voxelswithin
the lung with an attenuation < 950 Hounsfield units (HU) at
full inspiration [% low attenuation area (LAA)  950insp] [28].
For percent emphysema,we used<5% as a normal limit based
on measurements from healthy non-smoking controls and
10% as a criteria of significant emphysema [29,30]. Airway
analysis was performed using the PulmonaryWorkstation Plus
(VIDA Diagnostics, Inc., Coralville, IA). In each segmental
Heterogeneity of GOLD 1 1471bronchus, the wall area (WA) and lumen area (LA) were
measured. The segmental wall area% was defined as
100  WA/(WA þ LA). The square root of the wall area of a
hypothetical 10mm internal perimeter airway (Pi10)was used
as another measure of airway disease. Additional variable
definitions are available in e-Appendix 1.
Epidemiological analysis
Comparisons of continuous variables between groups were
made using a Wilcoxon rank sum test or KruskaleWallis test,
as appropriate. Chi-square or Fisher’s exact tests were used
for categorical variables. Statistical analyses were per-
formed using R (2.15.1). A Venn diagram was generatedTable 1 Characteristics of subjects with GOLD Stage 1 in the COP
subjects according to lower limit of normal (LLN) values for FEV1
GOLD 1
(all subjects)
GOLD
FEV1
N 794 197
Age, yrs 61.7 (9.0) 68.1
Sex (% Male) 57.6 53.3
African American (%) 22.7 14.2
Current smoker (%) 55.8 38.1
Smoking pack-years 45.0 (24.6) 46.5
Body mass index,
kg/m2
27.1 (5.1) 27.9
FEV1% predicted 90.8 (9.0) 92.2
FVC% predicted 107.6 (12.4) 101.9
FEV1/FVC 0.65 (0.04) 0.68
Positive bronchodilator
responsiveness (%)
14.9 10.8
Total lung capacityCT%
predicted
102.6 (15.0) 100.4
% emphysema
(% LAA950insp)
5.2 (5.7) 4.7 (
% gas trapping
(%LAA856exp)
20.3 (12.3) 20.2
Segmental wall area% 60.3 (2.8) 60.1
Pi10 3.62 (0.11) 3.62
6 min walk distance, m 442 (105) 443 (
MMRC dyspnea score 0.8 (1.2) 0.6 (
Resting O2 saturation, % 96.7 (2.2) 96.5
Chronic bronchitis
(% affirmative)
15.7 9.6
Exacerbation frequency, per year 0.2 (0.7) 0.1 (
Severe exacerbation
(% affirmative)
4.9 4.1
Definition of abbreviations: LAAZ low attenuation area; LLNZ lower
Council; Pi10 Z square root of wall area for a hypothetical airway w
Data are presented as mean (standard deviation) or percent.
Bronchodilator responsiveness was considered positive if the change in
of short-acting inhaled beta-agonist.
For bronchodilator responsiveness, n Z 783.
For TLCCT, % emphysema, and segmental wall area %, n Z 760.
For % gas trapping, n Z 678.
For Pi10, n Z 750.
For respiratory medication use, n Z 782.using an automatic area-proportional Euler diagram draw-
ing tool available at http://www.eulerdiagrams.org/
eulerAPE/(eulerAPE 2.0.3., University of Kent, Canter-
bury, UK).
Cluster analysis
K-means clustering analyses were performed on a subset of
GOLD 1 subjects with complete data for three key input
variables which were selected to capture information
related to airflow, emphysema, and airway disease: post-
bronchodilator FEV1% predicted, %LAA950insp, and
segmental wall area%. We used normalized mutual infor-
mation [31] to determine the optimal number of clusters;DGene cohort and comparison between two groups of GOLD 1
/FVC.
1 with
/FVC  LLN
GOLD 1 with
FEV1/FVC < LLN
p-Value comparing
subjects above and
below LLN
597
(6.4) 59.7 (8.8) <0.001
59.0 NS
25.5 0.002
61.6 <0.001
(24.3) 44.5 (24.7) NS
(4.6) 26.8 (5.3) <0.001
(9.5) 90.3 (8.8) 0.011
(10.6) 109.5 (12.4) <0.001
(0.01) 0.64 (0.04) <0.001
16.3 NS
(14.7) 103.4 (15.1) 0.015
4.7) 5.4 (6.0) NS
(11.2) 20.3 (12.6) NS
(2.4) 60.4 (2.9) NS
(0.10) 3.62 (0.11) NS
105) 462 (105) 0.029
1.0) 0.9 (1.2) 0.025
(2.3) 96.8 (2.2) 0.036
17.8 0.009
0.6) 0.2 (0.7) NS
5.2 NS
limit of normal for FEV1/FVC; MMRCZmodified Medical Research
ith an internal perimeter of 10 mm.
FEV1 was 200 mL and  12% predicted following administration
1472 J.H. Lee et al.clustering and candidate gene testing were performed
separately in NHW and AA subjects using R (2.15.1).Genetic analysis
Genome-wide SNP genotyping data were obtained on the
Illumina (San Diego, CA) OmniExpress platform with addi-
tional genotypes imputed using MaCH [32] and minimac [33]
and 1000 Genomes [34] Phase I v3 using European (EUR) or
cosmopolitan reference panels for the NHWs and AAs,
respectively. Genome-wide association testing for binary
GOLD 1 status under an additive model, adjusting for age,
sex, pack-years of cigarette smoking, and principal com-
ponents for genetic ancestry was performed separately in
NHW and AA subjects using PLINK [35] with smokers with
normal lung function as a control group. Fixed-effectsTable 2 Comparisons according to the presence or absence of
COPDGene study enrollment among subjects with GOLD stage 1.a
No ex
N 684
Age, yrs 61.8 (
Sex (% male) 59.4
African American (%) 22.8
Current smoker (%) 56.4
Smoking pack-years 44.7 (
Body mass index, kg/m2 27.0 (
FEV1% predicted 90.9 (
FVC% predicted 107.4
FEV1/FVC 0.65 (
Positive bronchodilator responsiveness (%) 14.3
Total Lung CapacityCT% predicted 102.3
% emphysema (% LAA950insp) 5.1 (5
% gas trapping (%LAA856exp) 20.4 (
Segmental wall area% 60.2 (
Pi10 3.62 (
6 min walk distance, m 459 (1
MMRC dyspnea score 0.7 (1
Resting O2 saturation, % 96.8 (
Chronic bronchitis (% affirmative) 13.9
Exacerbation frequency, per year 0
Physician-diagnosed asthma (% affirmative) 10.7
Short-acting beta-agonist use (% affirmative) 12.1
Long-acting beta-agonist use (% affirmative) 0.6
Ipratropium use (% affirmative) 0.7
Tiotropium use (% affirmative) 4.6
Inhaled corticosteroid use (% affirmative) 2.8
Oral corticosteroid use (% affirmative) 0.6
Definition of abbreviations: LAAZ low attenuation area; MMRCZ mo
for a hypothetical airway with an internal perimeter of 10 mm.
Data are presented as mean (standard deviation) or percent.
Bronchodilator responsiveness was considered positive if the change in
of short acting inhaled beta-agonist.
For bronchodilator responsiveness, n Z 783.
For TLCCT, % emphysema, and segmental wall area%, n Z 760.
For % gas trapping, n Z 678.
For Pi10, n Z 750.
For respiratory medication use, n Z 782.
a Thirteen subjects who indicated that they had an ER visit or hospit
the question “Have you had a flare-up of your chest trouble in the lameta-analysis [36] of these two racial groups was per-
formed using METAL (version 2010-08-01) [37] and R 2.15.1
(www.r-project.org) with the meta-package. In addition to
the genome-wide analysis, SNPs within genomic regions
which have previously been identified to be associated with
moderate-to-severe COPD or emphysema at genome-wide
significance were further investigated. The single most
significant previously reported SNP from the HHIP, FAM13A,
RAB4B, and BICD1 regions was included; for the chromo-
some 15q25 region, which may contain multiple COPD sus-
ceptibility loci, two SNPs were selected. These COPD
genome-wide significant SNPs were used in genetic associ-
ation analysis comparing GOLD 1 subjects to smoking con-
trols, and each GOLD 1 cluster to smoking controls; in
addition, genetic association analysis with FEV1 (% pre-
dicted) was performed in GOLD 1 and combined subjects of
GOLD 1 and smoking controls.any respiratory exacerbations in the one year period before
acerbation Exacerbation p-Value
110
8.9) 61.3 (9.6) NS
46.4 0.014
21.8 NS
51.8 NS
23.5) 46.9 (30.6) NS
5.0) 27.7 (5.8) NS
9.0) 90.1 (9.2) NS
(12.1) 108.8 (14.2) NS
0.04) 0.64 (0.05) NS
18.7 NS
(14.8) 104.5 (16.2) NS
.2) 6.1 (7.8) NS
12.2) 19.8 (13.1) NS
2.7) 60.8 (3.1) 0.04
0.11) 3.64 (0.11) NS
06) 442 (102) NS
.1) 1.6 (1.3) <0.001
2.2) 96.2 (2.7) NS
27.3 0.001
1.6 (1.2) <0.001
30.9 <0.001
54.1 <0.001
6.4 <0.001
4.6 0.007
18.3 <0.001
12.8 <0.001
1.9 NS
dified Medical Research Council; Pi10 Z square root of wall area
FEV1 was 200 mL and  12% predicted following administration
alization in the past year but who did not respond affirmatively to
st 12 months” were included in the exacerbation group.
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Epidemiology
The number of GOLD 1 subjects enrolled in COPDGene was
794. Comparisons between GOLD 1 subjects with LLN-COPD
and those with LLN-normal are summarized in Table 1.
Subjects meeting both GOLD 1 and LLN-COPD criteria, as
expected, were younger; however, we also found higher
proportions of AAs and current smokers, decreased BMI and
increased total lung capacity measured by CT, as well as an
increased prevalence of chronic bronchitis, relative to LLN-
normal subjects. While MMRC dyspnea score of LLN-COPD
subjects was higher, their mean six-minute walk distance
was longer than that of LLN-Normal. However, there were
no differences in percentages of emphysema and gas
trapping, segmental wall area%, Pi10, exacerbation fre-
quency, history of severe exacerbations, and frequency of
respiratory medication use between GOLD 1 LLN-COPD andTable 3 Comparisons according to percent emphysema among
% LAA-95
N 487
Age, yrs 60.7 (9.0
Sex (% Male) 52.4
African American (%) 24.6
Current smoker (%) 64.5
Smoking pack-years 43.5 (23
Body mass index, kg/m2 27.3 (5.1
FEV1% predicted 90.6 (8.7
FVC% predicted 106.5 (1
FEV1/FVC 0.66 (0.0
Positive bronchodilator responsiveness (%) 16.3
Total lung capacityCT% predicted 99.8 (14
% emphysema (% LAA-950insp) 2.0 (1.4)
% gas trapping (%LAA-856exp) 16.3 (11
Segmental wall area% 60.7 (2.9
Pi10 3.64 (0.1
6 min walk distance, m 456 (97)
MMRC dyspnea score 0.75 (1.1
Resting O2 saturation, % 96.9 (2.1
Chronic bronchitis (% affirmative) 16.0
Exacerbation frequency, per year 0.2 (0.7)
Severe exacerbation (% affirmative) 4.5
Short-acting beta-agonist use (% affirmative) 16.4
Long-acting beta-agonist use (% affirmative) 1.0
Ipratropium use (% affirmative) 0.8
Tiotropium use (% affirmative) 3.5
Inhaled corticosteroid use (% affirmative) 4.2
Oral corticosteroid use (% affirmative) 0.6
Definition of abbreviations: LAA Z low attenuation area; MMRCZ mo
for a hypothetical airway with an internal perimeter of 10 mm.
Data are presented as mean (standard deviation) or percent.
Bronchodilator responsiveness was considered positive if the change in
of short-acting inhaled beta-agonist.
For bronchodilator responsiveness, n Z 598.
For % gas trapping, n Z 549.
For Pi10, n Z 600.
For respiratory medication use, n Z 599.LLN-Normal subjects. The prevalence of comorbidities in
these two groups of GOLD 1 subjects was similar except for
diabetes mellitus, hypertension and hyperlipidemia, which
were more prevalent in LLN-normal subjects likely related
to their older mean age. Physician-diagnosed asthma and
COPD were reported in 13.5% and 31% of all GOLD 1 sub-
jects, respectively, and 6.5% received a diagnosis of both
asthma and COPD. There were no differences in the rates of
physician-diagnosed asthma or physician-diagnosed COPD
between the two LLN-defined GOLD 1 groups.
Table 2 shows comparisons according to the presence or
absence of any respiratory exacerbation in the year prior to
study participation among GOLD 1 subjects. Subjects with a
history of any respiratory exacerbation were more likely to
be female, and they had increased segmental wall area%,
higher MMRC dyspnea score, and increased prevalence of
chronic bronchitis and physician-diagnosed asthma
compared to those without history of exacerbation. Except
for oral corticosteroids, all respiratory medications weresubjects with GOLD stage 1.
0insp <5% % LAA-950insp 10% p-Value
121
) 65.2 (7.7) <0.001
68.6 0.002
16.5 NS
30.6 <0.001
.7) 52.2 (27.9) 0.002
) 26.2 (5.1) 0.016
) 92.5 (10.9) NS
2.3) 112.7 (13.9) <0.001
4) 0.62 (0.06) <0.001
13.4 NS
.8) 107.6 (14.6) <0.001
15.8 (5.8) <0.001
.1) 32.3 (11.0) <0.001
) 59.3 (2.4) <0.001
1) 3.58 (0.10) <0.001
465 (123) NS
6) 0.96 (1.28) NS
) 96.0 (2.6) <0.001
15.7 NS
0.2 (0.5) NS
5.8 NS
23.3 NS
3.3 NS
2.5 NS
19.2 <0.001
5.8 NS
0.8 NS
dified Medical Research Council; Pi10 Z square root of wall area
FEV1 was 200 mL and  12% predicted following administration
1474 J.H. Lee et al.more frequently used in those with an exacerbation history.
However, the prevalence of measured comorbidities did not
show any differences between these two groups.
Table 3 compares GOLD 1 subjects with and without
significant emphysema. Among subjects with significant
emphysema, there were more males, fewer current
smokers, higher pack-years of smoking, lower BMI, lower
segmental wall area%, and lower Pi10 compared with those
without significant emphysema. Tiotropium was more
frequently used in subjects with higher% emphysema.
There were no differences in frequency of exacerbation
and prevalence of comorbidities between these groups
except for coronary artery disease. These epidemiological
analyses suggest substantial heterogeneity within the GOLD
1 group, which is illustrated in Fig. 1.
Cluster analysis
To further explore heterogeneity in GOLD 1 subjects, we
performed cluster analysis. The subset of GOLD 1 subjects
with complete data for FEV1% predicted, % emphysema,
and segmental wall area% included in the cluster analysis
(n Z 760) did not differ from the full cohort of GOLD 1
subjects with respect to mean age, pack-years of cigarette
smoking, BMI, or distribution by gender or current smoking
status. Normalized mutual information analysis demon-
strated high cluster reproducibility for kZ 4 clusters (Table
E1). The results of k-means clustering in NHW subjects with
GOLD 1 are summarized in Table 4. Members of cluster 1
demonstrated the highest post-bronchodilator FEV1%Figure 1 Venn diagram for clinical heterogeneity of GOLD
1). ) The area for each group and the area of overlap are
proportional to the number of subjects. LLN: lower limit of
normal for FEV1/FVC. LLN-Normal subjects have FEV1/FVC
values greater than or equal to this threshold, while LLN-COPD
subjects have FEV1/FVC below this threshold. Exacerbation:
the presence of any respiratory exacerbations in the one year
period before COPDGene study enrollment. % emphysema: the
percentage of voxels within the lung with an
attenuation < 950 Hounsfield units (HU) from volumetric
chest CT measurements at full inspiration [% low attenuation
area (LAA)950insp].predicted; we refer to this cluster as a putative “near-
normal subtype”. Members of cluster 2 have the youngest
age, the highest BMI and segmental wall area%, the highest
proportion of chronic bronchitis and bronchodilator
responsiveness, and the shortest 6 min walk distance; we
refer to this cluster as a putative “airway-predominant
subtype”. Members of cluster 3 have the oldest age, the
lowest BMI, the highest% emphysema, % gas trapping, and
MMRC dyspnea score, the lowest rate of current smoking
but the highest pack-years, and the lowest resting O2
saturation; we refer to this cluster as the “emphysema-
predominant subtype”. Finally, members of cluster 4 show
the lowest post-bronchodilator FEV1% predicted and rate of
bronchodilator responsiveness; we refer to this as the
“lowest FEV1% predicted subtype”.
Table E2 shows the results of k-means clustering in AA
GOLD 1 subjects on the left and the results of clustering AA
GOLD 1 subjects by using clustering centers of NHW sub-
jects on the right. The reproducibility rate of assigning AA
subjects using these two methods was 75%.Genetics
After genotyping and quality control, 587 subjects with
GOLD 1 and 2534 smoking controls were included for ge-
netic analysis of NHWs, and 161 GOLD 1 subjects and 1749
smoking controls were included for genetic analysis of AAs.
GWAS of all GOLD 1 subjects relative to smoking controls for
each of NHWs and AAs did not include any SNPs that
reached the genome-wide significance threshold
(p < 5  108) (Table E3 and E4, Fig. E1 and E2). The most
significantly associated SNPs for all GOLD 1 subjects relative
to smoking controls were: rs6084592 on chromosome 20p13
(RNF24, p Z 1.06  107) in NHW and rs114095670 on
9p13.3 (RECK, p Z 5.92  108) in AA. Neither a meta-
analysis of NHWs and AAs nor additional analyses with
adding current/former smoking status as an adjustment
variable led to any SNPs meeting genome-wide significance.
GWAS of each GOLD 1 cluster relative to smoking con-
trols was performed separately in NHW and AA subjects;
only SNPs with minor allele frequencies (MAFs) above 5%
were analyzed. There were only two genome-wide signifi-
cant SNPs, rs7268680 near to KIF16B on 20p12.1 with MAF of
0.09 (pZ 1.67  108) in the lowest FEV1 GOLD 1 cluster of
NHWs (n Z 219) and rs17669292 near to TAF13 on 1p13.3
with MAF of 0.1 (pZ 3.35  108) in the lowest FEV1 GOLD
1 cluster of AAs (n Z 66). Further replication of these
cluster-specific findings will be required, since the sample
sizes are quite small for a GWAS.
Since the GWAS results in our relatively small sample
size of GOLD 1 subjects were not genome-wide significant,
we assessed genetic variants associated with COPD or
emphysema previously reported to be genome-wide sig-
nificant in the literature including rs7671167 (4q22,
FAM13A); rs1980057 (4q31, HHIP); rs13180 and rs1051730
(15q25, IREB2/CHRNA3); rs161976 (12p11, BICD1); and
rs7937 (19q13, RAB4B) [22e26]. These SNPs were examined
for associations with GOLD 1 relative to smoking controls,
GOLD 1 cluster relative to smoking controls, and post-
bronchodilator FEV1% predicted among combined subjects
with GOLD 1 and smoking controls or only GOLD 1 subjects.
Table 4 Results of k-means clustering for k Z 4 clusters in non-Hispanic white subjects with GOLD 1 (N Z 594).
Feature Near-normal Airway-
predominant
Emphysema-
predominant
Lowest FEV1%
predicted
p-Valuea
N 104 201 68 221
Variables used to classify
FEV1% predicted 105.9 (8.1) 88.3 (5.5) 88.9 (6.9) 87.0 (4.6) <0.001
% Emphysema 5.8 (4.7) 2.9 (2.6) 17.3 (5.6) 4.2 (2.9) <0.001
Segmental wall area% 58.6 (2.0) 62.8 (1.8) 59.1 (2.1) 58.6 (1.6) <0.001
Variables used to assess
clusters
Age, yrs 64.5 (8.7) 61.9 (9.5) 65.6 (6.8) 63.4 (8.3) 0.012
Sex (% male) 66.3 55.2 69.1 55.2 NS
Body mass index, kg/m2 26.5 (5.1) 28.1 (5.2) 26.1 (4.3) 26.5 (4.2) 0.001
Current smoker (%) 52.9 54.7 20.6 43.0 <0.001
Smoking pack-years 43.0 (20.8) 46.4 (25.1) 55.1 (27.4) 44.9 (23.7) 0.01
FVC% predicted 122.4 (13.0) 103.2 (8.8) 110.1 (11.2) 102.2 (8.2) <0.001
FEV1/FVC 0.65 (0.04) 0.65 (0.04) 0.61 (0.06) 0.65 (0.04) <0.001
FEF 25e75% 1.58 (0.57) 1.32 (0.48) 1.21 (0.48) 1.25 (0.45) <0.001
Positive bronchodilator
responsiveness (%)
12.6 18.7 16.4 10.5 NS
Total lung capacityCT%
predicted
111.2 (14.4) 100.6 (15.3) 109.2 (13.3) 103.0 (13.3) <0.001
% Emphysema upper third 5.9 (6.1) 3.0 (3.7) 21.1 (9.3) 4.9 (4.7) <0.001
% Emphysema lower third 6.1 (4.8) 3.1 (2.9) 14.1 (7.2) 4.1 (3.1) <0.001
% Emphysema upper
3rd/lower 3rd ratio
1.2 (1.5) 1.9 (4.8) 2.6 (4.5) 2.1 (3.8) <0.001
% Gas trapping 21.7 (10.4) 16.7 (10.9) 34.7 (8.9) 19.5 (9.9) <0.001
6 min walk distance, m 495 (99) 457 (97) 485 (98) 469 (93) 0.015
MMRC dyspnea score 0.40 (0.81) 0.78 (1.16) 0.91 (1.28) 0.73 (1.12) 0.027
Resting O2 saturation, % 96.8 (2.0) 96.7 (2.1) 95.8 (2.4) 96.5 (2.4) 0.023
Chronic bronchitis
(% affirmative)
11.5 21.9 16.2 13.1 0.046
Exacerbation frequency,
per year
0.1 (0.4) 0.3 (0.9) 0.2 (0.6) 0.2 (0.7) 0.036
SGRQ score symptoms 21.2 (20.0) 30.3 (24.1) 27.0 (25.6) 23.6 (23.0) 0.003
SGRQ score active 16.6 (17.6) 26.9 (24.0) 28.1 (26.0) 23.9 (23.1) 0.004
SGRQ score impact 6.1 (10.7) 12.7 (16.3) 13.5 (16.6) 9.8 (14.3) <0.001
SGRQ score total 11.6 (12.4) 19.8 (18.1) 20.1 (19.4) 16.3 (16.8) <0.001
Definition of abbreviations: MMRC Z Modified Medical Research Council; SGRQ Z St. George Respiratory Questionnaire.
Data are presented as mean (standard deviation) or percent. Bronchodilator responsiveness was considered positive if the change in
FEV1 was 200 mL and  12% predicted following administration of short-acting inhaled beta-agonist.
a KruskaleWallis test comparing four clusters.
Heterogeneity of GOLD 1 1475In NHWs, the only SNP nominally associated with GOLD 1
status relative to smoking controls was rs7671167 (FAM13A)
in both univariate and multiple logistic regression models
with adjustment for age, sex, pack-years of cigarette
smoking and genetic ancestry principal components (Table
5). In the analysis of GOLD 1 clusters, we noted a general
lack of genetic associations in the near-normal and airway-
predominant clusters; however, nominally significant asso-
ciations were found between the emphysema-predominant
GOLD 1 cluster and SNPs near FAM13A (rs7671167) and
BICD1 (rs161976). The lowest FEV1% predicted cluster was
associated with rs1980057 (HHIP) and rs1051730 (CHRNA3)
(Table 6). While two SNPs, rs1051730 (CHRNA3) and rs7937
(RAB4B), were associated with post-bronchodilator FEV1%
predicted in the combined group of GOLD 1 and smoking
control subjects in both univariate and multiple linear
regression models with adjustment for pack-years ofcigarette smoking and the genetic ancestry principal com-
ponents, rs1980057 (HHIP) was associated with FEV1% pre-
dicted in subjects with GOLD 1 in only univariate linear
regression analysis (Table 7).
In AAs, the only SNP nominally associated with GOLD 1
status relative to smoking controls was rs1051730 (CHRNA3)
in both univariate and multiple logistic regression models
(Table E5). In the analysis of AA GOLD 1 clusters compared
to AA smoking controls, nominally significant association
was found between the near-normal GOLD 1 cluster and
rs1051730 (CHRNA3) (Table E6). In AAs, there were no SNPs
associated with post-bronchodilator FEV1% predicted in the
combined group of GOLD 1 and smoking control subjects or
in only GOLD 1 subjects.
In NHWs but not in AAs, the number of COPD risk alleles
based on four previously reported COPD genome-wide sig-
nificant associations, consisting of rs7671167 (FAM13A),
Table 5 Logistic regression analyses of previously identified COPD GWAS SNPs with GOLD 1 (nZ 587) relative to smokers with
normal lung function (n Z 2534) among non-Hispanic white subjects.a
Locus Nearest
gene
SNP Risk/non-risk
allele
Odds ratio 95% CI p-Valuey
4q22 FAM13A rs7671167 T/C 1.15 1.01e1.32 0.035
4q31 HHIP rs1980057 C/T 1.13 0.99e1.29 0.064
15q25 IREB2 rs13180 T/C 1.12 0.98e1.29 0.091
15q25 CHRNA3 rs1051730 A/G 1.15 1.00e1.32 0.050
12p11 BICD1 rs161976 G/A 1.05 0.93e1.20 NS
19q13 RAB4B rs7937 T/C 1.03 0.90e1.17 NS
yp-Values < 0.1 are expressed.
a Adjusted for age, sex, pack-years of cigarette smoking and genetic ancestry as summarized in the principal components.
Table 6 Logistic regression analyses of previously identified COPD GWAS SNPs with each GOLD 1 cluster relative to smokers
with normal lung function (n Z 2534) in non-Hispanic white subjects.a
Locus Nearest
gene
SNP Risk/non-
risk allele
Airway-predominantb
vs. smoking controls
Emphysema-predominantc
vs. smoking controls
Lowest FEV1% predicted
d
vs. smoking controls
OR (95% CI) p{ OR (95% CI) p{ OR (95% CI) p{
4q22 FAM13A rs7671167 T/C 1.15 (0.93e1.42) NS 1.57 (1.10e2.25) 0.014 1.11 (0.91e1.36) NS
4q31 HHIP rs1980057 C/T 1.09 (0.89e1.34) NS 1.32 (0.93e1.90) NS 1.26 (1.03e1.55) 0.024
15q25 IREB2 rs13180 T/C 1.08 (0.87e1.34) NS 0.94 (0.65e1.37) NS 1.20 (0.97e1.48) 0.092
15q25 CHRNA3 rs1051730 A/G 0.99 (0.79e1.23) NS 0.92 (0.62e1.34) NS 1.34 (1.09e1.65) 0.006
12p11 BICD1 rs161976 G/A 1.07 (0.87e1.32) NS 1.54 (1.08e2.22) 0.020 0.98 (0.81e1.20) NS
19q13 RAB4B rs7937 T/C 0.99 (0.80e1.22) NS 1.33 (0.94e1.93) NS 0.95 (0.78e1.16) NS
{p-Values < 0.1 are expressed.
a Adjusted for age, sex, pack-years of cigarette smoking and genetic ancestry as summarized in the principal components.
b For the airway-predominant GOLD 1 cluster, n Z 198.
c For the emphysema-predominant GOLD 1 cluster, n Z 68.
d For the lowest FEV1% predicted GOLD 1 cluster, n Z 219.
1476 J.H. Lee et al.rs1980057 (HHIP), rs1051730 (CHRNA3), and rs7937
(RAB4B), were negatively associated with post-
bronchodilator FEV1% predicted (p < 0.001) and positively
associated with % emphysema among combined subjects
with GOLD 1 and smoking controls (p Z 0.022, Fig. 2), but
not in only GOLD 1 subjects.Discussion
This study demonstrates that substantial phenotypic het-
erogeneity of COPD exists even in individuals with mildTable 7 Linear regression analyses of previously identified COP
combined group of GOLD 1 and smoking control subjects or only
Locus Nearest
gene
SNP Risk/non-
risk allele
GOLD 1 and sm
Risk allele
frequency
4q22 FAM13A rs7671167 T/C 0.49
4q31 HHIP rs1980057 C/T 0.58
15q25 IREB2 rs13180 T/C 0.61
15q25 CHRNA3 rs1051730 A/G 0.35
12p11 BICD1 rs161976 G/A 0.56
19q13 RAB4B rs7937 T/C 0.55
yp-Values < 0.1 are expressed.
a Adjusted for pack-years of cigarette smoking and genetic ancestrairflow limitation. We also found that genetic variants
previously associated with moderate-to-severe COPD
demonstrate evidence for genetic associations with
reduced lung function and clustering-derived clinical sub-
types of GOLD 1 subjects. Our findings provide suggestive
evidence that at least part of the observed phenotypic
heterogeneity in GOLD 1 subjects is related to genetic
variants.
Previous studies that have focused on subjects with mild
airflow obstruction are rare. Recently, a physiological study
showed that the respiratory system reached its physiologic
limit in mild COPD at a lower peak work rate and ventilationD GWAS SNPs with post-bronchodilator FEV1% predicted in a
GOLD 1 subjects among non-Hispanic white subjects.a
oking controls GOLD 1
b p-Valuey Risk allele
frequency
b p-Valuey
0.25 NS 0.52 0.54 NS
0.42 NS 0.60 1.23 0.026
0.06 NS 0.63 0.09 NS
0.67 0.023 0.37 0.25 NS
0.15 NS 0.57 0.32 NS
0.75 0.006 0.56 0.13 NS
y as summarized in the principal components.
Figure 2 Mean (A) post-bronchodilator FEV1% predicted (N Z 3121) and (B) percent emphysema (N Z 2984) according to the
number) of known COPD risk allele for rs7671167 (FAM13A), rs1980057 (HHIP), rs1051730 (CHRNA3) and rs7937 (RAB4B) in non-
Hispanic white subjects with GOLD 1 or normal lung function.
Heterogeneity of GOLD 1 1477than in healthy participants [16]. Although most of the
GOLD 1 subjects in our study did not have severe emphy-
sema or functional limitations, a small number of GOLD 1
subjects had severe emphysema (>20%) and even resting
hypoxemia. We found clinical heterogeneity of GOLD 1
population in various aspects. Firstly, we compared GOLD 1
subjects with LLN-COPD to those with LLN-normal. Those
with LLN-COPD had some evidence for increased respiratory
symptoms compared to LLN-normal subjects, based on their
higher mean MMRC score and increased prevalence of
chronic bronchitis, but they had better exercise perform-
ancedwhich may relate to their younger mean age. We
found that GOLD 1 subjects with a history of respiratory
exacerbations had increased respiratory symptoms (chronic
bronchitis and dyspnea) and increased respiratory medica-
tion use. The GOLD 1 subjects with a history of respiratory
exacerbations exhibited thicker airway walls and increased
prevalence of chronic bronchitis compared to those without
an exacerbation in the year before study enrollment. Pre-
viously, many studies have reported increased risk of COPD
exacerbations in patients with chronic bronchitis [7,38,39].
Also, GOLD 1 subjects with a history of respiratory exac-
erbations reported physician-diagnosed asthma more
frequently compared to those without, which is consistent
with a previous study demonstrating increased frequency of
exacerbations in patients with moderate-to-severe COPD
and a history of physician-diagnosed asthma compared to
those without a history of physician-diagnosed asthma [40].
In order to provide insights into the substantial clinical
heterogeneity which we observed, we selected post-
bronchodilator FEV1% predicted, % emphysema, and
segmental wall area% for cluster analysis; these variables
were chosen based on many previous studies demonstrating
that these phenotypes represent key components of COPD,
including airflow limitation, parenchymal destruction, and
airway disease, respectively [5,28,30,41,41,42]. K-means
clustering showed four discrete subgroups,whichwere similar
in NHW and AA subjects. The airway-predominant cluster is
characterizedbypoorexerciseperformanceandqualityof life
in spite of relatively young age, low percentages of emphy-
sema and gas trapping, and high rate of post-bronchodilatorresponse, which may be related to their high prevalence of
chronic bronchitis and increased airway wall thickness. While
airway- and emphysema-predominant GOLD 1 clusters
represent two classic phenotypes [2], the near-normal cluster
may represent individuals who have a reduced FEV1/FVC but
are otherwise well. Of interest, their mean FVC% predicted
value exceeds the normal upper limit (122.4%) in contrastwith
a normal mean FEV1% predicted (105.9%).
Even though GWASs of GOLD 1 relative to smoking con-
trols revealed no genome-wide significant associations in
both NHWs and AAs, the top SNP in AA subjects,
rs114095670, was nearly genome-wide significant and is
located within RECK, a negative regulator of MMP9 [43,44],
which was previously reported by our group to be regulated
by HHIP in human bronchial epithelial cells [45]. In both
NHWs and AAs, the airway-predominant GOLD 1 cluster did
not show any significant associations with previously iden-
tified COPD risk alleles. Interestingly, SNPs nominally asso-
ciated (p < 0.05) with the emphysema-predominant NHW
GOLD 1 cluster relative to smoking controls were different
from those associated with the lowest FEV1% predicted
cluster. These results support the concept that clinical
heterogeneity of COPD may be closely related to genetic
heterogeneity. An SNP associated with the emphysema-
predominant NHW GOLD 1 cluster, rs161976 (BICD1), was
previously demonstrated in GWAS for emphysema in COPD
patients with FEV1 < 80% predicted [24]. The lowest FEV1%
predicted subgroup had the lowest rate of post-
bronchodilator response, suggesting fixed airway obstruc-
tion. Each subtype may have, at least in part, a different set
of genetic susceptibility determinants. Even though the
known COPD genome-wide significant SNPs do not provide a
complete explanation for COPD, the number of risk alleles
at four previously reported COPD GWAS loci correlated with
post-bronchodilator FEV1% predicted in the group of
COPDGene subjects with normal FEV1 values (smoking con-
trols and GOLD 1). Thus, we reconfirmed that these COPD
risk alleles, identified in GWAS of moderate-to-severe COPD
[22,23,25,26], likely play a role in mild COPD as well.
Our study is the largest detailed description of GOLD 1
reported to date and demonstrates a relationship between
1478 J.H. Lee et al.genetic variation and clinical heterogeneity. However, our
study did have several important limitations. Despite the
size of our study, the number of subjects is still small in the
context of GWAS and likely limits our ability to detect novel
genetic variants. It is not yet clear whether known pre-
dictors of lung function decline or future respiratory ex-
acerbations in moderate-to-severe COPD will be applicable
for GOLD 1. Whether our four clusters will demonstrate
stability or progression to advanced COPD stages will need
to be addressed with longitudinal studies.
Clinically useful subtypes in subjects with mild airflow
limitation should be helpful for individualized treatment
and/or risk prediction. The currently available evidence is
not adequate to create such a clinically useful set of GOLD
1 subtypes with certainty; replication of our proposed
subtypes in other study populations will be necessary. In
addition, genetic markers may be useful to define GOLD 1
subtypes; for example, our results suggest that an NHW
subject with risk alleles for both FAM13A and BICD1 might
have an increased risk of emphysema, while an NHW sub-
ject with risk alleles for HHIP and CHRNA3might experience
accelerated decline of FEV1. These conjectures will also
need to be validated in other study populations.
In summary, we have reported epidemiological and
radiographic characteristics of GOLD 1 subjects, explored
clinically relevant putative subtypes, and analyzed genetic
associations with these subtypes. The current study has
clearly shown substantial clinical heterogeneity of GOLD 1
subjects; our results also suggest that different genetic
determinants may influence different GOLD 1 subtypes.
Future work including larger numbers of GOLD 1 subjects
for genetic association studies as well as longitudinal
follow-up of GOLD 1 subjects may provide new insights into
COPD progression and therapeutic approaches.Conflicts of interest
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